In Brief: Patent extensions
This article was originally published in The Tan Sheet
Executive Summary
Patent extensions: Provisions sought as amendments to Congress' omnibus appropriations bill -- including extensions for AHP's Lodine, SmithKline Beecham's Relafen and Schering-Plough's Claritin and Eulexin, and an amendment from Sen. Joseph Biden (D-Del.) that would have overturned the decision in Merck v. Kessler -- were not included in the continuing resolution. J&J's reimbursement request for Haldol Medicaid drug rebates also was not addressed by legislators before the Oct. 4 adjournment of the 104th Congress...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning